Adaptive Biotechnologies Corporation $ADPT Shares Sold by Royal Bank of Canada

Royal Bank of Canada reduced its position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 40.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 46,470 shares of the company’s stock after selling 32,205 shares during the period. Royal Bank of Canada’s holdings in Adaptive Biotechnologies were worth $645,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies during the 4th quarter worth approximately $28,000. EverSource Wealth Advisors LLC grew its position in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares during the last quarter. KBC Group NV purchased a new position in shares of Adaptive Biotechnologies during the first quarter worth approximately $45,000. Assetmark Inc. raised its position in Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies during the 4th quarter worth $51,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. BTIG Research increased their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Morgan Stanley raised their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. TD Cowen lifted their target price on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Guggenheim boosted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average target price of $24.42.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT opened at $25.99 on Monday. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $26.16. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The firm’s 50-day simple moving average is $22.06 and its 200-day simple moving average is $17.34. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -63.39 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business’s revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) EPS. As a group, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

Insider Activity at Adaptive Biotechnologies

In other news, CEO Chad M. Robins sold 278,676 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $24.48, for a total transaction of $6,821,988.48. Following the transaction, the chief executive officer directly owned 2,180,518 shares of the company’s stock, valued at $53,379,080.64. This represents a 11.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Peter M. Neupert sold 124,690 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $25.15, for a total transaction of $3,135,953.50. Following the completion of the transaction, the director owned 130,625 shares of the company’s stock, valued at $3,285,218.75. This represents a 48.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 2,062,325 shares of company stock worth $46,659,069. 5.70% of the stock is currently owned by insiders.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.